179 related articles for article (PubMed ID: 38499860)
21. The Osteoclast in Bone Metastasis: Player and Target.
Maurizi A; Rucci N
Cancers (Basel); 2018 Jun; 10(7):. PubMed ID: 29954079
[TBL] [Abstract][Full Text] [Related]
22. Sodium-dependent phosphate transporters in osteoclast differentiation and function.
Albano G; Moor M; Dolder S; Siegrist M; Wagner CA; Biber J; Hernando N; Hofstetter W; Bonny O; Fuster DG
PLoS One; 2015; 10(4):e0125104. PubMed ID: 25910236
[TBL] [Abstract][Full Text] [Related]
23. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
[TBL] [Abstract][Full Text] [Related]
24. Metal-Organic Framework Nanoparticles for Ameliorating Breast Cancer-Associated Osteolysis.
Pang Y; Fu Y; Li C; Wu Z; Cao W; Hu X; Sun X; He W; Cao X; Ling D; Li Q; Fan C; Yang C; Kong X; Qin A
Nano Lett; 2020 Feb; 20(2):829-840. PubMed ID: 31916446
[TBL] [Abstract][Full Text] [Related]
25. Na+-dependent phosphate transporters in the murine osteoclast: cellular distribution and protein interactions.
Khadeer MA; Tang Z; Tenenhouse HS; Eiden MV; Murer H; Hernando N; Weinman EJ; Chellaiah MA; Gupta A
Am J Physiol Cell Physiol; 2003 Jun; 284(6):C1633-44. PubMed ID: 12606316
[TBL] [Abstract][Full Text] [Related]
26. Small molecule nAS-E targeting cAMP response element binding protein (CREB) and CREB-binding protein interaction inhibits breast cancer bone metastasis.
Jiang M; Yan Y; Yang K; Liu Z; Qi J; Zhou H; Qian N; Zhou Q; Wang T; Xu X; Xiao X; Deng L
J Cell Mol Med; 2019 Feb; 23(2):1224-1234. PubMed ID: 30461194
[TBL] [Abstract][Full Text] [Related]
27. Direct effect of calcium channel antagonists on osteoclast function: alterations in bone resorption and intracellular calcium concentrations.
Ritchie CK; Maercklein PB; Fitzpatrick LA
Endocrinology; 1994 Sep; 135(3):996-1003. PubMed ID: 8070395
[TBL] [Abstract][Full Text] [Related]
28. Osteoblast-n-Osteoclast: Making Headway to Osteoporosis Treatment.
Kaur M; Nagpal M; Singh M
Curr Drug Targets; 2020; 21(16):1640-1651. PubMed ID: 32735518
[TBL] [Abstract][Full Text] [Related]
29. Degradation of hydroxyapatite in vivo and in vitro requires osteoclastic sodium-bicarbonate co-transporter NBCn1.
Riihonen R; Nielsen S; Väänänen HK; Laitala-Leinonen T; Kwon TH
Matrix Biol; 2010 May; 29(4):287-94. PubMed ID: 20079835
[TBL] [Abstract][Full Text] [Related]
30. The role of osteoclasts in breast cancer bone metastasis.
Le Pape F; Vargas G; Clézardin P
J Bone Oncol; 2016 Sep; 5(3):93-95. PubMed ID: 27761364
[TBL] [Abstract][Full Text] [Related]
31. Tetraspanin 4 stabilizes membrane swellings and facilitates their maturation into migrasomes.
Dharan R; Huang Y; Cheppali SK; Goren S; Shendrik P; Wang W; Qiao J; Kozlov MM; Yu L; Sorkin R
Nat Commun; 2023 Feb; 14(1):1037. PubMed ID: 36823145
[TBL] [Abstract][Full Text] [Related]
32. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
33. Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity.
van't Hof RJ; Ralston SH
J Bone Miner Res; 1997 Nov; 12(11):1797-804. PubMed ID: 9383684
[TBL] [Abstract][Full Text] [Related]
34. Migrasome and Tetraspanins in Vascular Homeostasis: Concept, Present, and Future.
Zhang Y; Wang J; Ding Y; Zhang J; Xu Y; Xu J; Zheng S; Yang H
Front Cell Dev Biol; 2020; 8():438. PubMed ID: 32612990
[TBL] [Abstract][Full Text] [Related]
35. Osteoblast proliferation and differentiation on dentin slices are modulated by pretreatment of the surface with tetracycline or osteoclasts.
Schwartz Z; Lohmann CH; Wieland M; Cochran DL; Dean DD; Textor M; Bonewald LF; Boyan BD
J Periodontol; 2000 Apr; 71(4):586-97. PubMed ID: 10807123
[TBL] [Abstract][Full Text] [Related]
36. Osteoclasts direct bystander killing of cancer cells in vitro.
Ramnaraine M; Pan W; Clohisy DR
Bone; 2006 Jan; 38(1):4-12. PubMed ID: 16139579
[TBL] [Abstract][Full Text] [Related]
37. Increased bone resorption by osteoclast-specific deletion of the sodium/calcium exchanger isoform 1 (NCX1).
Albano G; Dolder S; Siegrist M; Mercier-Zuber A; Auberson M; Stoudmann C; Hofstetter W; Bonny O; Fuster DG
Pflugers Arch; 2017 Feb; 469(2):225-233. PubMed ID: 27942992
[TBL] [Abstract][Full Text] [Related]
38. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.
Ohshiba T; Miyaura C; Inada M; Ito A
Br J Cancer; 2003 Apr; 88(8):1318-26. PubMed ID: 12698202
[TBL] [Abstract][Full Text] [Related]
39. Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth.
Kreps LM; Addison CL
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805598
[TBL] [Abstract][Full Text] [Related]
40. The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation.
Sutherland A; Forsyth A; Cong Y; Grant L; Juan TH; Lee JK; Klimowicz A; Petrillo SK; Hu J; Chan A; Boutillon F; Goffin V; Egan C; Tang PA; Cai L; Morris D; Magliocco A; Shemanko CS
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26586670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
